Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Via News Knowledge File

NVIDIA Corporation

organization80% conf.·synced Oct 14, 2026

Technology company specializing in semiconductors and AI chips, IPO in 1999, Taiwan semiconductor dependency

60
sourced metrics
5477
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
228.52USD
Oct 13, 2026reference only
Price 52 Week Low
165.17USD
Oct 13, 2026reference only
Stock Return Ytd
21.0%
Oct 13, 2026reference only
Market Cap
5530184000000USD
Oct 13, 2026reference only
Price 52 Week High
239.24USD
Oct 13, 2026reference only
Shares Outstanding
24200000000.0shares
May 15, 2026reference only
Gross Profit
61157000000.0USD
Apr 26, 2026reference only
Stockholders Equity
195474000000.0USD
Apr 26, 2026reference only
Net Income
58321000000.0USD
Apr 26, 2026reference only
Total Liabilities
64000000000.0USD
Apr 26, 2026reference only
Operating Income
53536000000.0USD
Apr 26, 2026reference only
Rd Expense
6321000000.0USD
Apr 26, 2026reference only
Total Assets
259474000000.0USD
Apr 26, 2026reference only
Cost Of Revenue
20458000000.0USD
Apr 26, 2026reference only
Operating Cash Flow
50344000000.0USD
Apr 26, 2026reference only
Revenue
81615000000.0USD
Apr 26, 2026reference only
Cash
13237000000.0USD
Apr 26, 2026reference only
Eps
2.39USD_per_share
Apr 26, 2026reference only

Stated objectives

Regain billions of dollars in lost business through China market

source
target: billions stated

Share 15% or more of revenue from China sales with US government

source
target: 15 stated

Commission over 1 million square feet for manufacturing Blackwell chips in Arizona and AI supercomputers in Texas

source
target: 1 million square feet stated

Ramp up mass production of AI supercomputers in Texas by September 2026

source
by 2026-09-01 00:00:00stated

Q4 FY2026 revenue target

source
target: $65.0 billion, plus or minus 2% by 2026-01-25 00:00:00stated

Q4 FY2026 GAAP gross margin target

source
target: 74.8%, plus or minus 50 basis points by 2026-01-25 00:00:00stated

Q4 FY2026 non-GAAP gross margin target

source
target: 75.0%, plus or minus 50 basis points by 2026-01-25 00:00:00stated

Start shipping H200 chips to China

source
by 2026-02-01 00:00:00stated

Deliver up to 10x reduction in inference token cost compared to Blackwell platform

source
target: 10x stated

Reduce number of GPUs needed to train MoE models by 4x compared to Blackwell

source
target: 4x reduction stated

Relationship graph · 5477 connections

Developed by
1328
Supplies to
909
Competes with
729
Covered by
505
Customer of
424
Employs
320
Invested in
224
Partners with
176

Via News coverage

Micron Is Spending Twice as Fast as Two Years Ago, and Its Cash Pile Has Just Hit $25 Billion
October 8, 2026
Everyone Plans to Deploy AI Agents. The Bottleneck Is the Data, and the Spending Is Following It
October 7, 2026
Nvidia's Costs Have Quadrupled in Two Years While Only 45% of Company Data Is Ready for AI Agents
October 4, 2026
AI Agents Are Moving Into Banks and Insurers Faster Than the Data Behind Them, and the Money Is Following the Chips
September 29, 2026
Chip Fundamentals Keep Compounding While the Tape Reprices Sharply Lower
August 16, 2026
AI Chip Sector Repricing: Vicor's $11.3B Valuation Holds as Washington Takes a Stake in GlobalFoundries and Amkor Misses Guidance
August 15, 2026
Skyworks-Qorvo Merger, AMD-Cerebras Deal Advance as Chip Stocks Sink 25%
August 13, 2026
Chip Sector Splits: Record Amkor Earnings, $5B Nvidia-Backed SSI Deal Diverge From Stock Selloff
August 11, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com